AlphAIAlphAI — Financial news for AI agents
investing.comOCT 222 min read$ABT

Mizuho reiterates Neutral on Abbott Labs stock, keeps $115 target

Mizuho maintained a Neutral rating and $115 target for Abbott Labs (ABT), citing segment challenges and operational headwinds. ABT reported Q3 2026 earnings of $1.42 per share, meeting estimates, with revenue at $13.01B. The company lowered full-year sales guidance and plans to spin off its Nutrition business by 2027. BTIG cut its target to $125 but kept a Buy rating.

Original reporting
investing.com
Published Oct 22, 2026, 12:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ABT
Bearish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The earnings beat is offset by the guidance cut and restructuring, likely prompting a short‑term sell‑off while long‑term investors may reassess the company's growth profile.

02

Market read

Abbott's mixed earnings and strategic changes provide fresh material for traders, with immediate downside risk but potential longer‑term restructuring upside.

03

What to watch

Potential upside from the Volt launch and stable electrophysiology mapping business, plus dividend resilience.

Relevance 8/10Novelty 8/10Timing: today

Background

Abbott Laboratories reported Q3 2026 results with revenue of $13.01 bn and EPS of $1.42, beat estimates, but lowered full‑year sales guidance and announced a Nutrition business spin‑off by end‑2027.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Mizuho reiterated a Neutral rating on Abbott Laboratories, citing Q3 2026 earnings, a downward revision of full-year sales guidance and a planned spin‑off of the Nutrition business.

Expected impact

likely pressure as the market prices in the lower sales guidance and the uncertainty of the upcoming spin‑off.

Evidence & confidence

The article provides fresh earnings numbers, a guidance reduction and a strategic restructuring, all of which are new and material for a large‑cap stock.

Market effects

Sector

The nutrition spin‑off may create a new pure‑play nutrition company, affecting peers in the health‑care consumer segment.

Regional

U.S. healthcare sector may see modest re‑rating as analysts adjust expectations for Abbott.

Global

Limited; primarily impacts U.S. and global healthcare investors tracking Abbott.

Counterpoint

What could challenge this read

The spin‑off could unlock value in the Nutrition unit, and the guidance cut may be temporary, offering a buying opportunity at lower levels.

Key entities

  • Analyst
    Mizuho

    Reiterated Neutral rating and $115 price target for Abbott.

  • Analyst
    BTIG

    Reduced price target to $125 while maintaining Buy rating.

Read at source← All news

Related articles

OCT 23
$ABTMed

StoneX reiterates Buy on Abbott Labs stock, $120 target unchanged

StoneX reiterated a Buy rating and $120 target for Abbott Labs (ABT) after Q3 results. Abbott lowered its full-year revenue guidance to 6% and adjusted EPS to $5.50-$5.55. StoneX reduced its 2026 and 2027 revenue and EPS estimates. Abbott's Q3 revenue was $13.01B, up 7%, with adjusted EPS of $1.42. The company plans to spin off its Nutrition business by 2027. Analysts have mixed reactions to the guidance changes.

investing.com1 min
OCT 23
$ABTMedAI 8/10

Abbott’s colorectal cancer test shows improved sensitivity

Abbott (NYSE: ABT) presented data at the European Society for Medical Oncology Congress showing its Oncodetect test for colorectal cancer recurrence achieved 72.2% sensitivity, outperforming its previous version. The study analyzed 279 patients, detecting additional cases with the new test. Patients with detectable ctDNA had higher recurrence risk and lower survival rates. The test is not FDA-approved and is performed at Genomic Health Inc.

investing.com2 min
OCT 23
$ABTMedAI 8/10

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott (NYSE: ABT) presented data at ESMO 2026 showing its Oncodetect® test improved sensitivity for detecting colorectal cancer recurrence by 30% compared to its previous test. The study found a 10.6-fold higher recurrence risk for patients with detectable ctDNA. Abbott aims to connect innovations across cancer care, from early detection to post-treatment monitoring.

prnewswire.com2 min
OCT 22
$ABTMed

ABT Maintained by RBC Capital -- Price Target Lowered to $125

RBC Capital maintained an 'Outperform' rating on Abbott Laboratories (ABT) but lowered its price target from $130 to $125. GuruFocus values ABT at $135.74, suggesting a 24.9% undervaluation. The company has a GF Score of 82/100, indicating strong financial health and growth potential, but insiders have sold $46.85M in shares over the past three months.

gurufocus.com2 min